Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOX with or without panitumumab for previously untreated advanced oesophago-gastric cancer
ISRCTN65080435Phase 3Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- May 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of panitumumab, epirubicin, oxaliplatin and capecitabine in gastroesophageal adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Overall survival. Started May 2008; status: completed.
02
Drugs
panitumumabepirubicinoxaliplatincapecitabine
03
Conditions
gastroesophageal adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on ISRCTN65080435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN65080435.